Evidence map›Paper›PMID 39918000›Full record

ArticleInternational journal of oncology2025

Norchelerythrine from

Ji-Eun Lee, Byeol-Eun Jeon, Chan-Seong Kwon, Hyeon-Young Kim, Tae-Jin Kim, Youngseob Seo, Sang Hun Lee, Ho-Jin Shin, Sang-Woo Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ji-Eun LeeDepartment of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.
Byeol-Eun JeonDepartment of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.
Chan-Seong KwonDepartment of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.
Hyeon-Young KimDepartment of Molecular and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea.
Tae-Jin KimDepartment of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.
Youngseob SeoKorea Research Institute of Standard and Science, Daejeon 34113, Republic of Korea.
Sang Hun LeeDivision of Hematology‑Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 46241, Republic of Korea.
Ho-Jin ShinDivision of Hematology‑Oncology, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 46241, Republic of Korea.
Sang-Woo KimDepartment of Integrated Biological Science, Pusan National University, Busan 46241, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is the most prevalent form of leukemia in adults. The cornerstone of first‑line chemotherapy for AML has poor survival rates, underscoring the urgent need for development of novel therapeutic agents. Differentiation therapy targets the blockade of differentiation in myeloid progenitor cells. The present study screened 100 plant extracts native to South Korea to search for those with differentiation‑inducing activity in AML. Differentiation‑inducing activity was assessed by measuring CD11b expression using fluorescence activated cell sorting. Of these,

Indexed as

Antineoplastic Agents, PhytogenicCorydalisDNA DamageLeukemia, Myeloid, AcutePlant ExtractsAdultApoptosisCell Cycle CheckpointsCell DifferentiationCell Line, TumorCell SurvivalFemaleHL-60 CellsHumansMaleMiddle AgedAntineoplastic Agents, PhytogenicPlant Extractsacute myeloid leukemiaanti‑leukemic activityCorydalis incisa (Thunb.) Pers.differentiationDNA damage responsenorchelerythrine

Identifiers

PMID39918000
PMCPMC11837901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.